What it's for (Indications)
- Estradiol valerate and norgestrel, as a combined sequential hormonal therapy, are primarily indicated for the treatment of climacteric symptoms associated with natural or surgically induced menopause.
- These symptoms commonly include hot flashes, night sweats, vaginal dryness, and mood disturbances, significantly impacting quality of life.
- Furthermore, this medication is used for the prevention of osteoporosis in postmenopausal women at high risk of fractures who are intolerant of, or contraindicated for, other non-estrogen treatments, provided a thorough assessment of risks and benefits is conducted.
- It can also be prescribed for the regulation of irregular menstrual cycles, including cases of primary or secondary amenorrhea or oligomenorrhea, after a comprehensive diagnostic workup has excluded other underlying pathologies such as pregnancy, pituitary disorders, or thyroid dysfunction.
- The sequential progestin component is crucial for providing endometrial protection against estrogen-induced hyperplasia.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage regimen for estradiol valerate and norgestrel (e.g., Progyluton) typically involves a sequential administration designed to mimic the natural menstrual cycle, ensuring both symptom relief and endometrial protection. A common regimen involves taking one tablet daily without interruption, structured across a 21-day or 28-day cycle, depending on the specific product. For instance, the first 11 to 14 days may involve tablets containing only estradiol valerate, followed by 7 to 10 days of tablets containing both estradiol valerate and norgestrel. A tablet-free interval of 7 days often follows this, during which a withdrawal bleeding episode usually occurs, simulating a menstrual period. The exact dosage of each component (e.g., estradiol valerate 2 mg, norgestrel 0.5 mg) and the duration of each phase can vary based on the specific product formulation and the individual patient's symptoms, medical history, and response to therapy. It is crucial for patients to adhere strictly to the prescribed sequence and duration. Missed doses should be handled according to specific product instructions to maintain therapeutic efficacy and minimize breakthrough bleeding. Dosage adjustments should only be made under the direct supervision of a healthcare professional after careful clinical evaluation and consideration of the patient's risk profile. |
Safety & Warnings
Common Side Effects
- Common side effects associated with estradiol valerate and norgestrel therapy can include breast tenderness or pain, nausea, abdominal pain, bloating, and headaches, which are often transient and may diminish with continued use.
- Patients may also experience dizziness, mood disturbances (e.
- g.
- , depression, anxiety), changes in body weight (gain or loss), skin rashes, and altered libido.
- Vaginal spotting or bleeding outside the expected withdrawal bleeding period, particularly during the estrogen-only phase, should be reported.
- More serious adverse effects, though less common, include an increased risk of venous thromboembolism (VTE) such as deep vein thrombosis and pulmonary embolism, arterial thrombotic events including myocardial infarction and stroke, and gallbladder disease.
- There is also a potential increased risk of certain types of cancer, specifically breast and ovarian cancer with long-term use of combined hormone therapy, and endometrial cancer with unopposed estrogen.
- It is imperative that patients report any persistent, severe, or concerning side effects, especially signs of blood clots (e.
- g.
- , sudden chest pain, shortness of breath, severe leg pain and swelling, speech changes) or changes in breast tissue, to their healthcare provider immediately for prompt evaluation and management.
Serious Warnings
- Black Box Warning: **WARNING: CARDIOVASCULAR DISORDERS, MALIGNANT NEOPLASMS, AND PROBABLE DEMENTIA** **1. Cardiovascular Disorders:** Estrogens and progestins, including estradiol valerate and norgestrel, should not be used for the prevention of cardiovascular disease. The Women's Health Initiative (WHI) study reported an increased risk of myocardial infarction, stroke, venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) in postmenopausal women (50-79 years of age) receiving daily oral combined estrogen plus progestin therapy (conjugated estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg) compared to placebo. These risks were observed within the first year of therapy and persisted. Therefore, combined estrogen and progestin therapy should be prescribed at the lowest effective dose and for the shortest duration consistent with treatment goals. **2. Malignant Neoplasms:** The WHI study also reported an increased risk of invasive breast cancer in postmenopausal women aged 50-79 years receiving daily combined estrogen plus progestin therapy compared to placebo, with the risk becoming evident after an average of 4 years of use. Unopposed estrogen therapy increases the risk of endometrial cancer; the progestin component in this medication is included to reduce this risk. Long-term use of estrogen-alone and estrogen-plus-progestin therapy has been associated with an increased risk of ovarian cancer. Appropriate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurrent abnormal genital bleeding. **3. Probable Dementia:** The Women's Health Initiative Memory Study (WHIMS), an ancillary study of WHI, reported an increased risk of probable dementia in postmenopausal women 65 years of age or older receiving daily oral combined estrogen plus progestin therapy compared to placebo. It is unknown whether this finding applies to younger postmenopausal women. The use of hormone therapy is not recommended for the prevention of probable dementia.
- Patients initiating and continuing therapy with estradiol valerate and norgestrel should be regularly monitored, and the need for continued treatment re-evaluated periodically, especially considering the potential long-term risks associated with hormone therapy.
- Serious warnings include an increased risk of cardiovascular events, such as myocardial infarction and stroke, particularly in women aged 60 years or older or those with pre-existing cardiovascular risk factors.
- There is also an increased risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism.
- The risk of endometrial hyperplasia and carcinoma is significantly increased with unopposed estrogen therapy; however, the progestin component in this combination is specifically included to mitigate this risk by inducing secretory changes and shedding of the endometrium.
- Furthermore, an increased risk of breast cancer has been observed with combined estrogen-progestin therapy, typically after several years of use.
- Hepatic impairment, uncontrolled hypertension, severe hypertriglyceridemia, and conditions that may be exacerbated by fluid retention (e.
- g.
- , asthma, epilepsy, migraine, congestive heart failure) require careful consideration, dose adjustment, and close monitoring.
- Any unexplained abnormal vaginal bleeding, regardless of amount or timing, should be thoroughly investigated to rule out malignancy or other serious pathology.
- Discontinuation of therapy should be considered if jaundice, severe migraine, or significant increase in blood pressure occurs.
How it Works (Mechanism of Action)
Estradiol valerate is a synthetic ester of 17β-estradiol, which is the primary and most potent endogenous estrogen produced by the human ovary. Following oral administration, estradiol valerate is rapidly hydrolyzed to 17β-estradiol, which then exerts its therapeutic effects by binding with high affinity to estrogen receptors (ERα and ERβ) located in various target tissues throughout the body. These tissues include the uterus, breast, vagina, bone, hypothalamus, and pituitary gland. This binding initiates a cascade of intracellular events that modulate gene expression, leading to the physiological effects of estrogens, such as the alleviation of menopausal symptoms (e.g., vasomotor symptoms, vaginal atrophy) and the maintenance of bone mineral density. Norgestrel is a synthetic progestogen, a derivative of 19-nortestosterone. It acts by binding to progesterone receptors within target cells. In a combined sequential hormone therapy like this, norgestrel is included to counteract the proliferative effects of estrogen on the endometrium. Estrogen alone stimulates endometrial growth, which can lead to hyperplasia and an increased risk of endometrial carcinoma. Norgestrel induces secretory changes in the endometrium, promoting differentiation and shedding, thereby protecting against estrogen-induced endometrial proliferation and reducing the risk of endometrial cancer. The sequential administration of these hormones aims to mimic the natural menstrual cycle, typically resulting in regular withdrawal bleeding.
Commercial Brands (Alternatives)
No other brands found for this formula.